Case Reports
Treatment of Autoimmune Haemolytic Anaemia with Hepatitis C Virus-A Real Challenge
Authors:
A Basu ,
School of Tropical Medicine, IN
About A
MBBS MD, RMO cum Clinical Tutor, Department of Tropical Medicine, School of Tropical Medicine, 108 C R Avenue, Kolkata, India
D Nidhi,
School of Tropical Medicine, IN
About D
Assistant Professor, Department of Haematology
R Mehebubar,
School of Tropical Medicine, IN
About R
Associate Professor, Tropical Medicine
R Yogiraj,
School of Tropical Medicine, IN
About R
Assistant Professor, Tropical Medicine
G Rama Prosad
School of Tropical Medicine, IN
About G
Professor, Tropical Medicine
Abstract
Hepatitis C virus (HCV) infection is a potentially curable disease. The first line of treatment is pegylated interferon and ribavirin, both of which cause haemolysis. HCV itself causes autoimmune haemolytic anaemia (AIHA). Treatment of AIHA with steroid is contraindicated in patients on interferon. We report the successful treatment of a patient with AIHA infected with HCV whose treatment was a real challenge due to the risk of exacerbation of haemolysis by antiviral treatment. We describe the successful treatment of this patient initially with corticosteroids followed by pegylated interferon and gradual increase of the dose of ribavirin
How to Cite:
Basu, A. et al., (2016). Treatment of Autoimmune Haemolytic Anaemia with Hepatitis C Virus-A Real Challenge. Sri Lankan Journal of Infectious Diseases. 6(2), pp.130–133. DOI: http://doi.org/10.4038/sljid.v6i2.8115
Published on
26 Oct 2016.
Peer Reviewed
Downloads
